ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0294

Obesity and Risk of Autoimmune Diseases: Insights from the National Inpatient Sample

Sami Rabah and Xiangyi Kang, Lincoln Medical Center, New York, NY

Meeting: ACR Convergence 2024

Keywords: Autoinflammatory diseases, obesity, rheumatoid arthritis, risk assessment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Miscellaneous Rheumatic & Inflammatory Diseases Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Obesity has been implicated as a risk factor in developing various cardiovascular, respiratory, and other health complications. However, the link between obesity and autoimmune diseases is underrecognized. This study investigates the prevalence of obesity in patients with autoimmune diseases and evaluates the risks of autoimmune diseases in obese patients using a large national database.

Methods: Patients aged 18 or older, hospitalized between 2016 and 2019, with and without obesity (defined as a body mass index ≥30), and diagnosed with an autoimmune condition, including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and dermatomyositis, were identified from the National Inpatient Sample (NIS) database using the International Classification of Diseases, Tenth Revision (ICD-10) codes. Prevalence rates of obesity in patients with different autoimmune diseases were calculated. The adjusted odds ratios (AORs) for autoimmune diseases in obese patients were determined using logistic multivariate regression analysis, controlling for age, race, sex, and other comorbidities to assess the associations between autoimmune diseases and obesity.

Results: Over 13 million patients with obesity were identified. The prevalence of obesity in patients with autoimmune diseases varied, with notable findings in rheumatoid arthritis (14.66%), systemic lupus erythematosus (14.73%), and psoriatic arthritis (19.93%). Patients with obesity had higher odds of developing psoriatic arthritis (AOR 1.92, 95% Confidence Interval [CI]: 1.65-2.23, p < 0.001), rheumatoid arthritis (AOR 1.29, 95% CI: 1.28-1.30, p < 0.001), dermatomyositis (AOR 1.12, 95% CI: 1.03-1.21, p = 0.011), and systemic lupus erythematosus (AOR 1.17, 95% CI: 1.15-1.18, p < 0.001). Conversely, obese patients had lower odds of having systemic sclerosis (AOR 0.54 CI: 0.51-0.56, p < 0.001). These associations remained statistically significant after adjusting for age, sex, and other comorbidities.

See Figure 1 for prevalence rates and Figure 2 for the adjusted odds ratios displayed in a Forest plot.

Conclusion: This retrospective study demonstrates an association between obesity and the risk of developing certain autoimmune diseases. Further research is needed to explore the underlying mechanisms linking adiposity and autoimmune diseases.

Supporting image 1

Figure 1

Supporting image 2

Figure 2


Disclosures: S. Rabah: None; X. Kang: None.

To cite this abstract in AMA style:

Rabah S, Kang X. Obesity and Risk of Autoimmune Diseases: Insights from the National Inpatient Sample [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/obesity-and-risk-of-autoimmune-diseases-insights-from-the-national-inpatient-sample/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/obesity-and-risk-of-autoimmune-diseases-insights-from-the-national-inpatient-sample/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology